The New England journal of medicine, 2023-07, Vol.389 (4), p.309-321
- Dauvilliers, Yves
- Mignot, Emmanuel
- del Río Villegas, Rafael
- Du, Yeting
- Hanson, Elizabeth
- Inoue, Yuichi
- Kadali, Harisha
- Koundourakis, Elena
- Meyer, Seetha
- Rogers, Raquel
- Scammell, Thomas E.
- Sheikh, Sarah I.
- Swick, Todd
- Szakács, Zoltan
- von Rosenstiel, Philipp
- Wu, Jingtao
- Zeitz, Heidi
- Murthy, N. Venkatesha
- Plazzi, Giuseppe
- von Hehn, Christian
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Dauvilliers, Yves
- Mignot, Emmanuel
- del Río Villegas, Rafael
- Du, Yeting
- Hanson, Elizabeth
- Inoue, Yuichi
- Kadali, Harisha
- Koundourakis, Elena
- Meyer, Seetha
- Rogers, Raquel
- Scammell, Thomas E.
- Sheikh, Sarah I.
- Swick, Todd
- Szakács, Zoltan
- von Rosenstiel, Philipp
- Wu, Jingtao
- Zeitz, Heidi
- Murthy, N. Venkatesha
- Plazzi, Giuseppe
- von Hehn, Christian
- Titel
- Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1
- Ist Teil von
- The New England journal of medicine, 2023-07, Vol.389 (4), p.309-321
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- EZB Electronic Journals Library
- Beschreibungen/Notizen
- In a randomized trial involving patients with narcolepsy, an oral orexin receptor 2 agonist reduced sleepiness and cataplexy but had liver toxic effects.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2301940Titel-ID: cdi_proquest_miscellaneous_2843036967
- Format
- –
- Schlagworte
- Adverse events, Agonists, Cataplexy, Cerebrospinal fluid, Clinical outcomes, Critical Care, Critical Care General, Drug dosages, Drug withdrawal, Latency, Liver, Narcolepsy, Neurology, Neuropeptides, Neurosurgery, Orexins, Patients, Placebos, Pulmonary, Sleep, Sleep and wakefulness, Sleep disorders, Vital signs